| dc.contributor.author | Cuesta Sancho, Sara | |
| dc.contributor.author | Márquez Coello, María de las Mercedes | |
| dc.contributor.author | Illanes Álvarez, Francisco | |
| dc.contributor.author | Márquez Ruiz, Denisse | |
| dc.contributor.author | Arizcorreta Yarza, Ana | |
| dc.contributor.author | Galán Sánchez, Fátima | |
| dc.contributor.author | Montiel, Natalia | |
| dc.contributor.author | Rodríguez Iglesias, Manuel Antonio | |
| dc.contributor.author | Girón González, José Antonio | |
| dc.contributor.other | Biomedicina, Biotecnología y Salud Pública | es_ES |
| dc.contributor.other | Medicina | es_ES |
| dc.date.accessioned | 2022-07-12T10:21:30Z | |
| dc.date.available | 2022-07-12T10:21:30Z | |
| dc.date.issued | 2022-01 | |
| dc.identifier.issn | 1948-5182 | |
| dc.identifier.uri | http://hdl.handle.net/10498/27161 | |
| dc.description.abstract | Loss of follow-up or reinfections hinder the expectations of hepatitis C eradication
despite the existence of highly effective treatments. Moreover, the elimination of
the infection does not imply the reversion of those chronic alterations derived
from the previous infection by hepatitis C virus (HCV). This review analyzes the
risk factors associated with loss to follow-up in diagnosis or treatment, and the
possibility of reinfection. Likewise, it assesses the residual alterations induced by
chronic HCV infection considering the liver alterations (inflammation, fibrosis,
risk of decompensation, hepatocellular carcinoma, liver transplantation) and, on
the other hand, the comorbidities and extrahepatic manifestations (cryoglobulinemia,
non-Hodgkin lymphoma, peripheral insulin resistance, and lipid, bone
and cognitive alterations). Peculiarities present in subjects coinfected with human
immunodeficiency virus are analyzed in each section. | es_ES |
| dc.format | application/pdf | es_ES |
| dc.language.iso | eng | es_ES |
| dc.publisher | BAISHIDENG PUBLISHING GROUP INC | es_ES |
| dc.rights | Atribución-NoComercial 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | * |
| dc.source | World Journal of Hepatology, Vol. 14, Núm. 1, pp. 62-79 | es_ES |
| dc.subject | Hepatitis C virus | es_ES |
| dc.subject | Sustained virological response | es_ES |
| dc.subject | Direct antiviral agents | es_ES |
| dc.subject | Human immunodeficiency virus | es_ES |
| dc.subject | Cirrhosis decompensation | es_ES |
| dc.subject | Hepatocarcinoma | es_ES |
| dc.subject | Extrahepatic complications | es_ES |
| dc.title | Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response | es_ES |
| dc.type | journal article | es_ES |
| dc.rights.accessRights | open access | es_ES |
| dc.identifier.doi | 10.4254/WJH.V14.I1.62 | |
| dc.relation.projectID | info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI19%2F01361/ES/INFECCION POR VIH, FORMACION DE NETS Y ATEROSCLEROSIS/ | es_ES |
| dc.relation.projectID | info:eu-repo/grantAgreement/Junta de Andalucía//PI-0076-2017 | es_ES |